Physician profile
Thomas Young
NPI 1255337259
$4,374.58
in general payments reported to CMS, 2019-2025
35 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $218 · 2021: $351 · 2022: $507 · 2023: $244 · 2024: $880 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.24 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $1,375.92 | 2024-2025 | Daxxify |
| Janssen Biotech, INC. | $544.91 | 2019-2024 | Erleada, Rybrevant, Akeega |
| E.R. Squibb & Sons, L.L.C. | $318.13 | 2019-2022 | |
| Pfizer INC. | $291.48 | 2019-2024 | |
| Amgen INC. | $233.16 | 2019-2020 | |
| Daiichi Sankyo INC. | $203.33 | 2022-2025 | Datroway |
| Merck Sharp & Dohme LLC | $145.45 | 2019-2024 | Keytruda, Welireg |
| Allergan, INC. | $124.80 | 2019 | |
| Sobi, INC | $110.23 | 2024 | |
| Eisai INC. | $96.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $86.61 | 2019-2025 | |
| Adc Therapeutics America, INC. | $79.00 | 2025 | |
| Incyte Corporation | $72.27 | 2024-2025 | Jakafi, Niktimvo |
| Abbvie INC. | $68.01 | 2025 | |
| Celgene Corporation | $66.54 | 2019-2025 | Opdivo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.58 | 2021-2025 | Venclexta |
| Array Biopharma INC | $55.25 | 2021-2025 | Mektovi, Tukysa, Braftovi |
| Rigel Pharmaceuticals, INC. | $45.79 | 2019-2020 | |
| Tesaro, INC. | $39.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.98 | 2024 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $32.53 | 2019-2023 | Lynparza |
| Servier Pharmaceuticals LLC | $32.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.05 | 2019 | |
| Acrotech Biopharma INC. | $26.19 | 2021-2022 | |
| Pharmaessentia USA Corporation | $26.06 | 2022 | |
| Cti Biopharma Corp. | $23.48 | 2023 | Vonjo |
| Kite Pharma, INC. | $23.45 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Lilly USA, LLC | $18.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.09 | 2023 | Alunbrig |
| Pharmacosmos Therapeutics INC. | $16.48 | 2021 | |
| Emd Serono, INC. | $15.74 | 2021 | |
| Karyopharm Therapeutics INC. | $12.26 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Verastem, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.